Evaluation of the efficacy and safety of ((WartOver)) topical ointment for the treatment of cutaneous warts: a randomized triple-blind clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年2月7日

试验速览

暂无简介。

•Over 18 years of age
•The participant is able to understand the conditions and instructions of the clinical trial
•The presence of up to 5 skin warts with an area of up to 1 cm
•Presence of the lesion at least 4 weeks in the baseline visit
•At least 4 weeks have passed since other treatments such as cryotherapy and...
•Willing to sign an informed consent to participate in this study

•Pregnancy and lactation
•history of skin malignancy and premalignancy (eg, actinic keratosis)
•immunodeficiency (eg, due to chemotherapy, glucocorticoids, systemic steroids, genetic immunodeficiency, transplant status, AIDS, etc.)
•lesions in the genital area
•eyelid involvement
•complicated infection
•receipt of any human papillomavirus (HPV) vaccine within 6 months of enrollment
•any current skin disease or systemic disease (eg, psoriasis, atopic dermatitis, eczema, sun damage) or condition that, in the opinion of the researcher, participating in the study may expose the participant to unnecessary risk or interfere with the conduct of the study or evaluations, such as sunburn, excessive hair, open wounds.

发起方